real-world treatment outcomes of 1l axitinib pembrolizumab in patients with advanced rcc in the us
Published 2 years ago • 1K plays • Length 5:10Download video MP4
Download video MP3
Similar videos
-
2:31
axitinib plus pembrolizumab in advanced rcc
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
1:29
phase i/ii study of nivolumab and axitinib for advanced rcc
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc
-
1:00
pembrolizumab/axitinib and avelumab/axitinib combo for rcc
-
0:57
avelumab and axitinib for the treatment of advanced rcc
-
1:06
exciting potential of pembrolizumab combined with axitinib for kidney cancer
-
1:34
unmet needs in the treatment of renal cell carcinoma
-
0:59
combining lenvatinib & pembrolizumab for non-clear cell rcc: keynote-b61 study rationale
-
0:48
will immunotherapy take over the treatment landscape of patients high-risk renal cell carcinoma?
-
4:35
atlas trial: axitinib in rcc- despite reporting no significant difference, some optimism remains
-
1:45
real-world outcomes of mrcc in the current io & tki era
-
1:28
keynote-b61: first-line lenvatinib pembrolizumab in non-clear cell rcc
-
4:25
kidney cancer updates: avelumab/axitinib, pembro/axitinib, bevacizumab/atezo & ipilimumab/nivo
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc
-
0:53
unanswered questions in the management of clear cell rcc
-
0:42
the importance of obtaining real-world data
-
11:18
first-line icis in advanced non-clear cell rcc
-
1:05
cohort 1 litespark-003: belzutifan cabozantinib 1l treatment for advanced rcc